Baird Financial Group Inc. Has $131.61 Million Holdings in Abbott Laboratories $ABT

Key Points

• Baird Financial Group reduced its Abbott Laboratories stake by 16.4% in the second quarter, selling 283,527 shares and retaining 1.45 million shares valued at $131.61 million. Institutional investors own 75.18% of the company.
• Abbott beat quarterly expectations with $1.31 EPS and $12.59 billion in revenue, while revenue increased 13% year over year. The company guided to third-quarter 2026 EPS of $1.38–$1.46 and full-year EPS of $5.45–$5.60.
• Abbott declared a quarterly dividend of $0.63 per share, equivalent to a 2.4% annualized yield. Analysts maintain a “Moderate Buy” consensus rating with an average price target of $119.50, above the reported share price of $105.66.

Baird Financial Group Inc. cut its holdings in Abbott Laboratories (NYSE:ABT - Free Report) by 16.4% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,450,388 shares of the healthcare product maker's stock after selling 283,527 shares during the period. Baird Financial Group Inc. owned 0.08% of Abbott Laboratories worth $131,608,000 as of its most recent filing with the SEC.

Several other institutional investors also recently added to or reduced their stakes in ABT. MidAtlantic Capital Management Inc. acquired a new stake in Abbott Laboratories during the fourth quarter worth about $25,000. Cornerstone Financial Management LLC acquired a new position in Abbott Laboratories in the 4th quarter valued at approximately $25,000. Purpose Unlimited Inc. bought a new stake in shares of Abbott Laboratories in the 4th quarter worth approximately $25,000. Portfolio Resources Advisor Group Inc. acquired a new position in shares of Abbott Laboratories in the fourth quarter valued at $26,000. Finally, Abound Financial LLC bought a new stake in Abbott Laboratories in the 4th quarter valued at $26,000. 75.18% of the stock is owned by institutional investors.

Abbott Laboratories Stock Down 2.5%

Shares of NYSE ABT opened at $105.66 on Wednesday. The firm's 50-day moving average is $105.04 and its 200-day moving average is $99.95. Abbott Laboratories has a 1 year low of $81.97 and a 1 year high of $137.49. The firm has a market capitalization of $182.82 billion, a PE ratio of 34.19, a price-to-earnings-growth ratio of 2.01 and a beta of 0.59. The company has a current ratio of 1.38, a quick ratio of 0.97 and a debt-to-equity ratio of 0.57.

Abbott Laboratories (NYSE:ABT - Get Free Report) last announced its quarterly earnings data on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.28 by $0.03. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. The firm had revenue of $12.59 billion for the quarter, compared to analysts' expectations of $12.52 billion. During the same period last year, the firm earned $1.26 earnings per share. The business's revenue for the quarter was up 13.0% on a year-over-year basis. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. Equities analysts expect that Abbott Laboratories will post 5.52 EPS for the current year.

Abbott Laboratories Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Monday, August 17th. Investors of record on Wednesday, July 15th were paid a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a yield of 2.4%. The ex-dividend date of this dividend was Wednesday, July 15th. Abbott Laboratories's dividend payout ratio (DPR) is presently 81.55%.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on ABT shares. Weiss Ratings raised Abbott Laboratories from a "sell (d+)" rating to a "hold (c-)" rating in a report on Thursday, August 6th. Robert W. Baird started coverage on shares of Abbott Laboratories in a research report on Wednesday, July 1st. They set an "outperform" rating and a $121.00 target price for the company. The Goldman Sachs Group reduced their price target on shares of Abbott Laboratories from $121.00 to $113.00 and set a "buy" rating on the stock in a research report on Wednesday, May 27th. BTIG Research lifted their target price on shares of Abbott Laboratories from $131.00 to $134.00 and gave the company a "buy" rating in a research note on Friday, July 17th. Finally, Piper Sandler reiterated an "overweight" rating and issued a $118.00 price objective (up from $115.00) on shares of Abbott Laboratories in a research report on Friday, July 17th. Three equities research analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and four have assigned a Hold rating to the company's stock. Based on data from MarketBeat, Abbott Laboratories currently has a consensus rating of "Moderate Buy" and an average price target of $119.50.

About Abbott Laboratories

Abbott Laboratories NYSE: ABT is a global healthcare company that develops, manufactures and sells medical products and technologies. Its operations span four principal areas: medical devices, diagnostics, established pharmaceutical products and nutrition. Abbott serves healthcare providers, institutions and consumers in markets around the world.

The company's medical device portfolio includes products for cardiovascular care, diabetes management and other specialties. Its diagnostics business provides laboratory systems, tests and point-of-care solutions, while its nutrition products include infant, child and adult nutritional offerings sold under brands such as Similac, Ensure and Pedialyte.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.